Dec.08.2023
R & D
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary Endpoint
This material is intended to notify the press release issued on December 7 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
Please clickhttps://www.bms.com/media/press-releases.html for the original press release.